Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

Free AI-powered analysis and research for Arrowhead Pharmaceuticals, Inc. stock

Sector: Healthcare

Analyze Arrowhead Pharmaceuticals, Inc. (ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (ARWR) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into ARWR stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for Arrowhead Pharmaceuticals, Inc. stock.

📰 Latest Update

Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Sat, March 14, 2026 at 6:29 PM UTC 4 min read

Arrowhead Pharmaceuticals (ARWR) reported a significant revenue increase of $264 million for the first quarter of 2026, driven by the approval of its REDEMPLO treatment, marking a pivotal shift towards commercial operations. This approval not only enhances the company's product portfolio but also positions ARWR for potential long-term growth and profitability. Investors may view this development as a strong indicator of the company's future performance and market potential.

Read full article →

Why Analyze Arrowhead Pharmaceuticals, Inc. (ARWR) with StockIQ?

• ✅ Free AI-powered analysis of Arrowhead Pharmaceuticals, Inc. (ARWR) stock
• ✅ Real-time technical indicators for Arrowhead Pharmaceuticals, Inc. stock
• ✅ Comprehensive risk assessment for ARWR
• ✅ No credit card required

People also watch